Red Pill Formula Human Subjects in Clinical Trials
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
Still loading...
ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
Oxiracetam Clinical Trials482Pramiracetam Clinical Trials29Alpha-GPC Clinical Trials261Noopept Clinical Trials60MagnesiumX and TyrosineX Derivatives Clinical Trials53
2
Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.48Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers.12Cognitive Improvement In Mild To Moderate Alzheimer's Dementia After Treatment With The Acetylcholine Precursor Choline Alfoscerate: A Multicenter, Double-blind, Randomized, Placebo-controlled Trial 132[Noopept in the treatment of mild cognitive impairment in patients with stroke].6053
3
Effects of acute doses of oxiracetam in the scopolamine model of human amnesia.8Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia.Glycerophosphocholine Enhances Growth Hormone Secretion And Fat Oxidation In Young Adults
8[Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin].
4
Treatment trial of oxiracetam in Alzheimer's disease.12Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam.5Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise
7
5
Oxiracetam in dementia: a double-blind, placebo-controlled study.32Pharmacokinetics of oral pramiracetam in normal volunteers.12Optimization of a phytase-containing micronutrient powder with low amounts of highly bioavailable iron for in-home fortification of complementary foods.101
6
Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia.48L-alpha-glycerophosphocholine contributes to meat's enhancement of nonheme iron absorption.13
7
Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree.30
8
[Oxiracetam treatment of exogenous post-concussion syndrome. Statistical evaluation of results].18
9
Selegiline versus oxiracetam in patients with Alzheimer-type dementia.40
10
Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy.15
11
Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study31
12
[Oxiracetam].
13
Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia73
14
Organic brain syndrome treated with oxiracetam. A double-blind randomized controlled trial.53
15
Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.20
16
EEG changes induced by oxiracetam on diazepam-medicated volunteers.
12
17
Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study.22
18
Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life.20
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...
 
 
 
Sheet1